|Bid||133.38 x 100|
|Ask||133.42 x 100|
|Day's Range||132.56 - 134.44|
|52 Week Range||94.42 - 135.18|
|PE Ratio (TTM)||50.21|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Agio Pharmaceuticals saw its shares sink on Monday after the firm announced results from its midstage trial for the treatment of relapsed or refractory acute myeloid leukemia.
With biotech stocks like Celgene, Bluebird Bio and Regeneron on the move, cancer treatment developer Exelixis may be poised to pop into a new buy zone.
Corcept has been one of the best-performing drug stocks this year. These charts show why the good times could continue.